Spleen function is reduced in individuals with NR5A1 variants with or without DSD: a cross-sectional study.

NR5A1 DSD PPV-23 SF1 asplenism difference/disorder of sex development hyposplenism primary ovarian insufficiency spleen function

Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
21 Dec 2023
Historique:
received: 19 09 2023
revised: 06 12 2023
accepted: 13 12 2023
medline: 21 12 2023
pubmed: 21 12 2023
entrez: 21 12 2023
Statut: aheadofprint

Résumé

NR5A1 is a key regulator of sex differentiation and has been implicated in spleen development through transcription activation of TLX1. Concerns exist about hypo- or asplenism in individuals who have a difference of sex development (DSD) due to an NR5A1 disease-causing variant. We aimed to assess spleen anatomy and function in a clinical cohort of such individuals, and in their asymptomatic family member carriers. Cross-sectional assessment in 22 patients with a DSD or primary ovarian insufficiency and five asymptomatic carriers from 18 families, harboring 14 different NR5A1 variants. Spleen anatomy was assessed by ultrasound, spleen function by peripheral blood cell count, white blood cell differentiation, percentage of non-switched memory B-cells, specific pneumococcal antibody response, % pitted red blood cells and Howell-Jolly Bodies. Patients and asymptomatic heterozygous individuals had significantly decreased non-switched memory B-cells compared to healthy controls, but higher than asplenic patients. Thrombocytosis and spleen hypoplasia were present in 50% of heterozygous individuals. Four out of five individuals homozygous for the previously described p.(Arg103Gln) variant had asplenia. Individuals harbouring a heterozygous NR5A1 variant that may cause DSD have a considerable risk for functional hyposplenism, irrespective of their gonadal phenotype. Splenic function should be assessed in these individuals, and if affected or unknown, prophylaxis is recommended to prevent invasive encapsulated bacterial infections. The splenic phenotype associated with NR5A1 variants is more severe in homozygous individuals and is, at least for the p.(Arg103Gln) variant, associated with asplenism.

Identifiants

pubmed: 38128121
pii: 7486653
doi: 10.1093/ejendo/lvad174
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Martine Cools (M)

Department of Internal Medicine and Pediatrics, Ghent University, Pediatric Endocrinology Service, Ghent University Hospital, Ghent, Belgium.

Celien Grijp (C)

Department of Internal Medicine and Pediatrics, Ghent University, Pediatric Endocrinology Service, Ghent University Hospital, Ghent, Belgium.

Jana Neirinck (J)

Department of Diagnostic Science, Ghent University, Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.

Simon J Tavernier (SJ)

Department of Internal Medicine and Pediatrics, PID research lab, Ghent University, Ghent, Belgium.
Laboratory of Molecular Signal Transduction in Inflammation, Center for Inflammation Research, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.

Petra Schelstraete (P)

Department of Internal Medicine and Pediatrics, Ghent University, Pediatric Pulmonology and Infectious diseases, Ghent University Hospital, Ghent, Belgium.

Julie Van De Velde (J)

Department of Internal Medicine and Pediatrics, Ghent University, Pediatric Endocrinology Service, Ghent University Hospital, Ghent, Belgium.
Center for Medical Genetics, Ghent University Hospital; Department of Biomolecular Medicine, Ghent University, Belgium.

Lieve Morbée (L)

Department of Radiology, Ghent University Hospital, Ghent, Belgium.

Elfride De Baere (E)

Center for Medical Genetics, Ghent University Hospital; Department of Biomolecular Medicine, Ghent University, Belgium.

Carolien Bonroy (C)

Department of Diagnostic Science, Ghent University, Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.

Yolande van Bever (Y)

Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

Hennie Bruggenwirth (H)

Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

Clementien Vermont (C)

Department of Pediatric Infectious Diseases and Immunology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, the Netherlands.

Sabine E Hannema (SE)

Department of Pediatric Endocrinology, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, the Netherlands.
Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Paediatric Endocrinology, Gastroenterology Endocrinology Metabolism, Reproduction and Development, Amsterdam, The Netherlands.

Yolanda De Rijke (Y)

Department of Clinical Chemistry, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

Maha Abdulhadi-Atwan (M)

Department of Pediatrics, Pediatric Endocrinology Service, Palestine Red Crescent Society Hospital, Hebron, Palestine.

David Zangen (D)

Division of Pediatric Endocrinology, Hadassah University Hospital, Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Hannah Verdin (H)

Center for Medical Genetics, Ghent University Hospital; Department of Biomolecular Medicine, Ghent University, Belgium.

Filomeen Haerynck (F)

Department of Internal Medicine and Pediatrics, PID research lab, Ghent University, Ghent, Belgium.
Department of Pediatric Pulmonology and Immunology, Centre for Primary Immune deficiency, Jeffrey Modell Diagnostic and Research Centre for PID, Ghent University Hospital, Ghent, Belgium.

Classifications MeSH